Special Issue

Medicinal Chemistry and Pharmacological Activities of Heparin and Related Drugs

Message from the Guest Editor

In the last couple of years, there has been a resurgence of interest in heparin and related drugs. In part, this was fueled by the COVID-19 pandemic and the revelation that heparin and heparan sulfate can interact with the SARS-CoV-2 spike protein and inhibit SARS-CoV-2 infection in vitro. These findings came on the back of a greater appreciation that heparin has a wide range of activities that are not related to anti-coagulation, with its anti-inflammatory, anti-viral, and anti-cancer effects being particularly well known. This Special Issue aims to highlight the excitement felt by many of us in this field at these developments. The

journal *Pharmaceuticals* invites both reviews and original articles on the challenges and opportunities of developing heparin and heparin-inspired molecules for drugs targeting disease indications with inflammatory, viral or cancerous components. The collection of manuscripts will be published as a Special Issue entitled "Medicinal Chemistry and Pharmacological Activities of Heparin and Related Drugs".

Guest Editor

Prof. Dr. Deirdre R. Coombe

Curtin Medical School, Pharmacy and Biomedical Sciences, Curtin Health Innovation Research Institute, Faculty of Health Sciences, Curtin University, Perth, WA 6102, Australia

Deadline for manuscript submissions

closed (25 July 2024)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/114629

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





Pharmaceutica

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

